Xtandi (Enzalutamide)

Enzalutamide is a medicine used to treat prostate cancer. It works by blocking male hormones like testosterone from helping the cancer grow. It's taken by mouth as a capsule or tablet.

Brand names:Xtandi
Medication

What people taking Xtandi (Enzalutamide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Xtandi (Enzalutamide) for Prostate Cancer?

NameHow it went

About Xtandi (Enzalutamide)

What It's For

Enzalutamide, sold under the brand name Xtandi, is a prescription medicine for prostate cancer. It belongs to a group of drugs called androgen receptor inhibitors, a form of hormone therapy, and it is taken by mouth as a capsule or tablet. It is approved for three situations. The first is castration-resistant prostate cancer, meaning cancer that keeps growing even though treatment has brought testosterone down to very low levels. The second is metastatic castration-sensitive prostate cancer: cancer that has spread beyond the prostate but still responds to lowering testosterone. The third is for people whose PSA (prostate-specific antigen, a protein in the blood that tracks prostate cancer activity) rises again after surgery or radiation, with no spread visible on scans, in a pattern that signals a high risk of the cancer spreading. Doctors call this high-risk biochemical recurrence. In large trials, enzalutamide helped people in several of these settings live longer and delayed the cancer's growth or spread. It controls prostate cancer rather than curing it, and it is usually one part of a longer treatment plan.

How It Works

Most prostate cancers rely on androgens, the male sex hormones such as testosterone, to grow. Androgens work by attaching to a protein inside cells called the androgen receptor. The receptor then moves into the cell's nucleus and switches on genes that drive growth. Standard hormone therapy lowers how much testosterone the body makes. Enzalutamide works at the next step: it blocks androgens from attaching to the receptor and also keeps the receptor from reaching the cell's DNA. This can slow cancer that has learned to keep growing on very small amounts of testosterone, which is why enzalutamide is often added to testosterone-lowering treatment rather than replacing it.

Dosage & Administration

Enzalutamide comes as 40 mg capsules and as 40 mg and 80 mg tablets. The usual dose is 160 mg once a day (for example, four 40 mg capsules or two 80 mg tablets), taken at about the same time each day, with or without food. The prescriber may lower the dose if side effects are hard to tolerate, or adjust it if another medicine changes how much enzalutamide reaches the blood. Swallow each capsule or tablet whole with enough water to make sure it goes all the way down. Do not open, chew or dissolve capsules, and do not cut, crush or chew tablets. The pills are fairly large, and severe choking has occurred. Anyone who finds them hard to swallow should tell the care team; a smaller tablet size may help. For castration-resistant cancer and metastatic castration-sensitive cancer, enzalutamide is taken alongside ongoing testosterone-lowering therapy, usually a GnRH (gonadotropin-releasing hormone) medicine such as leuprolide injections, unless the testicles have been surgically removed. That therapy should continue while taking enzalutamide. For high-risk biochemical recurrence, enzalutamide may be used with or without it. If a dose is missed, take it as soon as you remember that day. If a whole day is missed, take the usual dose the next day; do not take extra to make up for it. Do not stop or change the dose without talking to the prescriber.

Side Effects

The most common side effects are tiredness, hot flashes, muscle and joint pain, constipation or diarrhea, reduced appetite and headache. Blood pressure also tends to rise: in trials, high blood pressure was reported in 14% of people taking enzalutamide compared with 7% taking a placebo, so it is worth checking regularly. Falls and broken bones are about twice as common as well. In trials, roughly 13% of people on enzalutamide had a fracture, compared with 6% on placebo. Dizziness or falls should be reported, and the care team may check bone health and fall risk and suggest bone-protecting treatment. Seizures are uncommon, affecting about 6 in 1,000 people in trials, but were seen in about 2 in 100 people in a study of those with risk factors such as a past seizure, brain injury, stroke or medicines that lower the seizure threshold. Anyone who has a seizure or loses consciousness should contact the care team right away; enzalutamide is stopped permanently after a seizure. A rare brain condition called PRES (posterior reversible encephalopathy syndrome) can cause a quickly worsening headache, confusion, drowsiness or vision changes, which also need prompt contact with the care team. Enzalutamide modestly raises the risk of heart problems caused by reduced blood flow to the heart. Chest pain or pressure, or other symptoms of a heart attack, need emergency care. Swelling of the face, lips, tongue or throat can be an allergic reaction: stop the medicine and seek medical help promptly, and call 911 if the swelling makes it hard to breathe or swallow. Rare, severe skin reactions with blistering or peeling have been reported since approval; a new widespread rash should be reported to the care team promptly.

Interactions & Warnings

Enzalutamide speeds up the liver enzymes that break down many other drugs, so it can make them less effective. This matters most for medicines where even a small drop in level could cause treatment to fail. Interactions also run the other way: gemfibrozil (a cholesterol and triglyceride medicine) raises enzalutamide levels, and rifampin (an antibiotic) lowers them, so both are generally avoided. Before starting, and whenever anything changes, the prescriber and pharmacist should review every prescription, over-the-counter medicine and herbal product, including any that may lower the seizure threshold. People who take digoxin, a heart medicine, should make sure the lab knows about enzalutamide, because it can make some digoxin blood tests read falsely high. Enzalutamide can harm a developing baby and cause pregnancy loss. Men taking it whose partner could become pregnant should use effective contraception during treatment and for 3 months after the last dose, and use a condom during sex with a pregnant partner. It may also reduce fertility, which is worth discussing before treatment for anyone who hopes to have children.

What to Expect

Enzalutamide is usually taken every day for the long term, continuing as long as it keeps the cancer under control and side effects remain manageable. Progress is followed with regular PSA blood tests and, at intervals, scans. A rising PSA or new findings on a scan can mean the cancer is growing again and a change in treatment may be needed. If a side effect becomes severe, the care team may pause enzalutamide for about a week and then restart it at the same or a lower dose. Ongoing follow-up usually includes blood pressure, heart risk factors such as diabetes and cholesterol, bone health and fall risk. Because of the seizure risk, it is worth discussing activities where a sudden loss of consciousness could cause serious harm, such as driving. For people treated for high-risk biochemical recurrence, the doctor may pause enzalutamide if PSA becomes undetectable after about 36 weeks of treatment and restart it if PSA rises again, with regular PSA checks during the break.

Questions to Ask Your Doctor

  1. 1.Why is enzalutamide a good fit for my stage of prostate cancer, and what other options do I have?
  2. 2.How will we track whether it is working, and how often will I have PSA tests and scans?
  3. 3.Do any of my current medicines or supplements interact with enzalutamide or raise my seizure risk?
  4. 4.What should we do to protect my bones, heart and blood pressure while I take it?
  5. 5.How long am I likely to take it, and is a treatment break ever an option for me?

Last reviewed • Oct 2026

Educational content, not medical advice.